High Court Won't Review Lamictal Pay-For-Delay Row
The U.S. Supreme Court on Monday declined to review a Third Circuit holding that pharmaceutical patent settlements lacking a cash payout can raise antitrust scrutiny, leaving in place a ruling that...To view the full article, register now.
Already a subscriber? Click here to view full article